Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Financial Outlook | Analysts project potential doubling of MACI revenues, with Canaccord Genuity setting a $57 price target. Explore the balance of growth potential and expansion costs |
Competitive Edge | Learn how MACI Arthro's unique approval pathway and arthroscopic application method strengthen Vericel's position in the cartilage repair market |
Market Expansion Strategy | Delve into Vericel's plans to tap into a $3 billion addressable market, targeting high-volume surgeons and expanding its sales force for MACI Arthro's success |
MACI Arthro Breakthrough | Explore Vericel's game-changing FDA approval for MACI Arthro, the only arthroscopic biologic cartilage repair product in the U.S., expanding its market reach |
Metrics to compare | VCEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVCELPeersSector | |
---|---|---|---|---|
P/E Ratio | 809.0x | −1.3x | −0.7x | |
PEG Ratio | 6.05 | 0.00 | 0.00 | |
Price / Book | 11.1x | 2.2x | 2.6x | |
Price / LTM Sales | 12.7x | 9.9x | 3.2x | |
Upside (Analyst Target) | 3.9% | 90.8% | 45.9% | |
Fair Value Upside | Unlock | 4.2% | 7.6% | Unlock |